Is CONFUSIONAL STATE a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed CONFUSIONAL STATE.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 131 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported CONFUSIONAL STATE to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and CONFUSIONAL STATE. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause CONFUSIONAL STATE, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes CONFUSIONAL STATE. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if CONFUSIONAL STATE ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing CONFUSIONAL STATE: 131
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where CONFUSIONAL STATE is a reported side effect: 3.9351%

FDA reports of any drug causing CONFUSIONAL STATE : 51107
Average percentage for all medicated patients where CONFUSIONAL STATE is reported as a complication: 0.3203%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with CONFUSIONAL STATE:

ASPIRIN (4401 patients)
LYRICA (2358 patients)
SEROQUEL (2083 patients)
NAMENDA (2077 patients)
OMEPRAZOLE (1853 patients)
LASIX (1838 patients)
NEURONTIN (1696 patients)
LISINOPRIL (1680 patients)
LIPITOR (1677 patients)
FUROSEMIDE (1668 patients)
SIMVASTATIN (1628 patients)
ACETAMINOPHEN (1601 patients)
PAXIL (1545 patients)
FOSAMAX (1535 patients)
DIGOXIN (1501 patients)
AMBIEN (1495 patients)
ATENOLOL (1493 patients)
PREDNISONE (1445 patients)
NEXIUM (1426 patients)
CYMBALTA (1385 patients)
XANAX (1384 patients)
VIOXX (1377 patients)
ZOLOFT (1351 patients)
ZOMETA (1337 patients)
OXYCONTIN (1322 patients)
HEPARIN SODIUM INJECTION (1319 patients)
COUMADIN (1297 patients)
LORAZEPAM (1296 patients)
SYNTHROID (1291 patients)
PLAVIX (1272 patients)
LEVOTHYROXINE SODIUM (1236 patients)
CHANTIX (1201 patients)
CLONAZEPAM (1170 patients)
DEXAMETHASONE (1138 patients)
GABAPENTIN (1107 patients)
LEXAPRO (1085 patients)
ATIVAN (1077 patients)
HYDROCHLOROTHIAZIDE (1043 patients)
PROTONIX (1032 patients)
DIAZEPAM (1032 patients)
AVONEX (1015 patients)
METFORMIN HCL (1000 patients)
TYSABRI (999 patients)
EFFEXOR (991 patients)
OXYCODONE HCL (989 patients)
ALLOPURINOL (987 patients)
FOLIC ACID (982 patients)
MORPHINE (978 patients)
POTASSIUM CHLORIDE (977 patients)
ZYPREXA (976 patients)
NORVASC (971 patients)
DURAGESIC-100 (966 patients)
ZOCOR (914 patients)
LEVAQUIN (898 patients)
RISPERDAL (897 patients)
TRAMADOL HCL (888 patients)
FORTEO (886 patients)
PRILOSEC (885 patients)
LANTUS (877 patients)
IBUPROFEN (871 patients)
WARFARIN SODIUM (865 patients)
ALBUTEROL (863 patients)
CLOZARIL (834 patients)
PROZAC (813 patients)
CITALOPRAM HYDROBROMIDE (807 patients)
TOPROL-XL (803 patients)
PERCOCET (798 patients)
FENTANYL (790 patients)
VICODIN (787 patients)
PREVACID (756 patients)
EXELON (750 patients)
CELEBREX (742 patients)
ARICEPT (741 patients)
RAMIPRIL (736 patients)
METOPROLOL TARTRATE (723 patients)
AREDIA (721 patients)
MORPHINE SULFATE (720 patients)
AMLODIPINE (712 patients)
PAROXETINE HCL (708 patients)
KLONOPIN (707 patients)
METHOTREXATE (703 patients)
VITAMIN D (699 patients)
DEPAKOTE (673 patients)
DECADRON (670 patients)
INSULIN (663 patients)
AMITRIPTYLINE HCL (662 patients)
ALPRAZOLAM (650 patients)
TRAZODONE HCL (650 patients)
OLANZAPINE (647 patients)
MIRTAZAPINE (643 patients)
ZOFRAN (634 patients)
REVLIMID (632 patients)
EFFEXOR XR (627 patients)
VALIUM (622 patients)
LAMICTAL (622 patients)
CELEXA (619 patients)
KEPPRA (608 patients)
WELLBUTRIN (602 patients)
CARBOPLATIN (581 patients)
PREDNISOLONE (580 patients)
TOPAMAX (577 patients)
CRESTOR (570 patients)
NITROGLYCERIN (566 patients)
CALCIUM (565 patients)
PREDNISONE TAB (561 patients)
BACLOFEN (558 patients)
MULTI-VITAMIN (547 patients)
LOVENOX (544 patients)
SPIRONOLACTONE (542 patients)
HUMIRA (539 patients)
CIPROFLOXACIN (535 patients)
TEGRETOL (529 patients)
COREG (526 patients)
LITHIUM CARBONATE (522 patients)
REMICADE (521 patients)
LANSOPRAZOLE (521 patients)
RIBAVIRIN (520 patients)
METOPROLOL (519 patients)
MULTI-VITAMINS (509 patients)
FLUOXETINE (505 patients)
ADVAIR DISKUS 100/50 (494 patients)
TEMAZEPAM (491 patients)
CLOZAPINE (491 patients)
BYETTA (491 patients)
LORTAB (477 patients)
ALDACTONE (469 patients)
RANITIDINE (469 patients)
PREMARIN (468 patients)
SPIRIVA (465 patients)
DIOVAN (462 patients)
ACYCLOVIR (461 patients)
ABILIFY (459 patients)
RISPERIDONE (458 patients)
COLACE (458 patients)
LACTULOSE (454 patients)
PARACETAMOL (453 patients)
GLUCOPHAGE (446 patients)
ENALAPRIL MALEATE (442 patients)
CISPLATIN (438 patients)
BACTRIM (435 patients)
VANCOMYCIN (435 patients)
AVASTIN (430 patients)
FLOMAX (428 patients)
AMOXICILLIN (424 patients)
GLYBURIDE (424 patients)
VELCADE (423 patients)
SINGULAIR (423 patients)
PEGASYS (419 patients)
COMPAZINE (416 patients)
HUMALOG (414 patients)
METOCLOPRAMIDE (412 patients)
PROMETHAZINE (409 patients)
AVELOX (403 patients)
VALPROATE SODIUM (400 patients)
ZOLPIDEM (398 patients)
DILAUDID (398 patients)
SEROQUEL XR (397 patients)
TYLENOL (397 patients)
CYCLOPHOSPHAMIDE (395 patients)
PANTOPRAZOLE (393 patients)
PEPCID (393 patients)
LOPRESSOR (392 patients)
REGLAN (391 patients)
VITAMIN B-12 (390 patients)
DILANTIN (390 patients)
ALTACE (389 patients)
NEXAVAR (384 patients)
COZAAR (383 patients)
HALDOL (383 patients)
FLEXERIL (381 patients)
ZANTAC (378 patients)
CARBAMAZEPINE (377 patients)
METFORMIN (375 patients)
GLIPIZIDE (372 patients)
CALCIUM CARBONATE (369 patients)
BENADRYL (368 patients)
PEG-INTRON (367 patients)
FERROUS SULFATE TAB (365 patients)
CLONIDINE (363 patients)
PROPRANOLOL (362 patients)
NAPROXEN (357 patients)
SINEMET (356 patients)
HEPARIN (354 patients)
VALTREX (352 patients)
ALLEGRA (352 patients)
FLUCONAZOLE (351 patients)
MS CONTIN (350 patients)
SUTENT (349 patients)
METHADONE HCL (346 patients)
ARANESP (344 patients)
FLUOROURACIL (342 patients)
ZYRTEC (338 patients)
REMERON (335 patients)
CLARITHROMYCIN (334 patients)
ULTRAM (327 patients)
HALOPERIDOL (326 patients)
RESTORIL (326 patients)
SANDOSTATIN LAR (325 patients)
SERTRALINE HYDROCHLORIDE (325 patients)
ACETYLSALICYLIC ACID SRT (324 patients)
BISOPROLOL FUMARATE (323 patients)
ELAVIL (320 patients)
ATORVASTATIN CALCIUM (316 patients)
NYSTATIN (315 patients)
VITAMIN E (312 patients)
TYLENOL (CAPLET) (312 patients)
PANTOPRAZOLE SODIUM (310 patients)
MIRALAX (310 patients)
AUGMENTIN '125' (309 patients)
LAMOTRIGINE (309 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about CONFUSIONAL STATE and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.